Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)
China · Delayed Price · Currency is CNY 12.70
+0.26 (2.09%)
Sep 30, 2026, 3:04 PM CST
SHE:301211 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 5,304 | 5,103 | 6,123 | 6,264 | 8,316 | 9,026 | |
Market Cap Growth | 6.81% | -16.66% | -2.25% | -24.68% | -7.87% | - |
Enterprise Value | 3,766 | 3,536 | 4,511 | 4,416 | 6,427 | 8,614 |
Last Close Price | 12.70 | 12.14 | 14.37 | 14.29 | 18.74 | 20.07 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 114.66 | 146.18 | 66.88 | 35.57 | 66.11 | 74.20 |
PS Ratio | 11.38 | 11.26 | 13.73 | 9.45 | 16.15 | 16.70 |
PB Ratio | 2.33 | 2.25 | 2.65 | 2.66 | 3.65 | 4.06 |
P/TBV Ratio | 2.40 | 2.31 | 2.73 | 2.74 | 3.77 | 4.19 |
P/FCF Ratio | - | - | - | - | 47.56 | 87.71 |
P/OCF Ratio | 166.58 | 675.83 | 63.73 | 45.70 | 33.16 | 72.80 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 8.08 | 7.80 | 10.12 | 6.66 | 12.48 | 15.93 |
EV/EBITDA Ratio | 68.34 | 84.19 | 84.03 | 26.66 | 67.14 | 62.68 |
EV/EBIT Ratio | - | - | 152.20 | 30.37 | 85.29 | 72.96 |
EV/FCF Ratio | - | - | - | - | 36.76 | 83.70 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
Debt / EBITDA Ratio | 0.03 | 0.07 | 0.09 | 0.04 | 0.08 | - |
Debt / FCF Ratio | - | - | - | - | 0.04 | - |
Net Debt / Equity Ratio | -0.67 | -0.68 | -0.71 | -0.77 | -0.86 | -0.84 |
Net Debt / EBITDA Ratio | -28.41 | -36.95 | -30.39 | -10.97 | -20.42 | -13.53 |
Net Debt / FCF Ratio | 52.38 | 34.66 | 23.87 | 36.73 | -11.18 | -18.07 |
Asset Turnover | 0.20 | 0.19 | 0.18 | 0.26 | 0.21 | 0.35 |
Inventory Turnover | 2.84 | 2.75 | 2.04 | 2.76 | 3.62 | 3.20 |
Quick Ratio | 16.09 | 14.43 | 10.47 | 10.86 | 10.01 | 19.65 |
Current Ratio | 17.65 | 15.64 | 11.40 | 11.98 | 10.66 | 20.67 |
Return on Equity (ROE) | 2.05% | 1.52% | 3.92% | 7.60% | 5.59% | 8.32% |
Return on Assets (ROA) | 0.26% | -0.01% | 0.74% | 3.60% | 1.95% | 4.71% |
Return on Invested Capital (ROIC) | 1.13% | -0.02% | 4.44% | 29.32% | 18.78% | 28.75% |
Return on Capital Employed (ROCE) | 0.40% | 0.00% | 1.30% | 6.10% | 3.30% | 5.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.88% | 0.68% | 1.49% | 2.81% | 1.51% | 1.35% |
FCF Yield | -0.55% | -0.88% | -1.12% | -0.79% | 2.10% | 1.14% |
Dividend Yield | 0.47% | 0.49% | 1.74% | 2.32% | 1.23% | 0.86% |
Payout Ratio | 53.88% | 206.24% | 151.00% | 54.51% | 57.24% | - |
Buyback Yield / Dilution | 4.81% | -4.87% | 0.60% | -0.97% | -33.19% | 1.01% |
Total Shareholder Return | 5.29% | -4.37% | 2.34% | 1.35% | -31.97% | 1.87% |